Home » Stocks » MGTX

MeiraGTx Holdings PLC (MGTX)

Stock Price: $15.63 USD 0.35 (2.29%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 678.53M
Revenue (ttm) 18.72M
Net Income (ttm) -53.01M
Shares Out 37.22M
EPS (ttm) -1.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $15.63
Previous Close $15.28
Change ($) 0.35
Change (%) 2.29%
Day's Open 15.28
Day's Range 14.70 - 15.83
Day's Volume 98,288
52-Week Range 9.31 - 21.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 5 days ago

MGTX has early proof of concept data for ophthalmic rare disease indications using its gene therapies. It has inked two deals with Janssen, one of them quite lucrative.

GlobeNewsWire - 1 month ago

Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET

GlobeNewsWire - 1 month ago

LONDON and NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbe...

GlobeNewsWire - 2 months ago

LONDON and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbe...

The Motley Fool - 2 months ago

The company announced the pricing of a public offering of common stock.

GlobeNewsWire - 2 months ago

LONDON and NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an unde...

GlobeNewsWire - 2 months ago

LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has commenced ...

GlobeNewsWire - 2 months ago

Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements in retinal sensitivity at 12 months Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements ...

GlobeNewsWire - 2 months ago

LONDON and NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbe...

GlobeNewsWire - 2 months ago

LONDON and NEW YORK,, Nov. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results fo...

GlobeNewsWire - 2 months ago

12-Month Dose Escalation Data from Phase 1/2 Clinical Trial to be Presented 12-Month Dose Escalation Data from Phase 1/2 Clinical Trial to be Presented

GlobeNewsWire - 3 months ago

LONDON and NEW YORK, Oct. 03, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced nine-month data from ...

GlobeNewsWire - 3 months ago

LONDON and NEW YORK, Sept. 28, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Fo...

GlobeNewsWire - 4 months ago

- Nine-Month Follow-Up Data to be Presented - - Nine-Month Follow-Up Data to be Presented -

Seeking Alpha - 4 months ago

MeiraGTx Is A Buy With Multiple Near-Term Catalysts As The Stock Is Weighed Down By Negative Sentiment

GlobeNewsWire - 5 months ago

- Positive initial data from Phase 1/2 clinical trial of AAV-RPGR for the treatment of XLRP recently presented - AAV-RPGR to advance into Phase 3 Lumeos clinical trial - Expands manufacturin...

GlobeNewsWire - 5 months ago

LONDON and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of ...

Zacks Investment Research - 5 months ago

MeiraGTx has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire - 6 months ago

• Data being presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting 

Zacks Investment Research - 6 months ago

MeiraGTx Holdings PLC (MGTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the nea...

Seeking Alpha - 9 months ago

MeiraGTx: An Exciting Gene Therapy Pick In March 2020

GlobeNewsWire - 10 months ago

LONDON and NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the European ...

Zacks Investment Research - 1 year ago

Does MeiraGTx Holdings PLC (MGTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 1 year ago

The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.

Other stocks mentioned: CHRS, MRNA, QURE, XOMA
GlobeNewsWire - 1 year ago

LONDON and NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a Park...

Zacks Investment Research - 1 year ago

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

Other stocks mentioned: NTLA, PIRS, QURE, VRTX, GNOM
Zacks Investment Research - 1 year ago

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

Other stocks mentioned: NTLA, PIRS, QURE, VRTX
The Motley Fool - 1 year ago

See why Glu Mobile, MeiraGTx, and Enphase Energy should be on your shopping list.

Other stocks mentioned: ENPH, GLUU
GlobeNewsWire - 1 year ago

LONDON and NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the Company wi...

The Motley Fool - 1 year ago

It was a great week for these three stocks, but can they continue climbing?

Other stocks mentioned: DOVA, KRYS
The Motley Fool - 1 year ago

Can these high-flying biotech stocks keep the momentum going?

Other stocks mentioned: ADVM, IOVA
Investors Business Daily - 1 year ago

Dow Jones component Johnson & Johnson could buy out biotech stock MeiraGTx for its efforts in gene therapy, an analyst suggested Friday. MeiraGTx is working on treatments for eye diseases.

Other stocks mentioned: JNJ

About MGTX

MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficien... [Read more...]

Industry
Biotechnology
Founded
2015
CEO
Alexandria Forbes
Employees
206
Stock Exchange
NASDAQ
Ticker Symbol
MGTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for MGTX stock is "Strong Buy." The 12-month stock price forecast is 36.17, which is an increase of 131.41% from the latest price.

Price Target
$36.17
(131.41% upside)
Analyst Consensus: Strong Buy